| Biomarker ID | 1760 |
| PMID | 29158798 |
| Year | 2017 |
| Biomarker | PSA concentration+Gleason grade+clinical T stage+ AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2; |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | NA |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 80 patients with tumor and 308 tumor free samples were taken from TCGA cohort for analysus |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.746 |
| Accuracy | 71.3% |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | National Institute for Health and Care Excellence (NICE) features were added to the model, which consist of PSA concentration, Gleason grade, and clinical T Stage. 5 fold cross validation used on data. SVM model created |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |